Which Dupixent (dupilumab) biosimilar is Celltrion developing?
Celltrion is developing a dupilumab biosimilar candidate under the company’s biosimilar pipeline. Public reporting around Celltrion’s dupilumab program has focused on progressing the development package (analytical similarity and clinical evaluation) required for a biosimilar regulatory submission.
Where is Celltrion in clinical development for its dupilumab biosimilar?
Details on exact trial phase, study titles, and enrollment timelines can vary by update. To track the most current status, the development and regulatory landscape for dupilumab biosimilars is also covered through patent/exclusivity research tools such as DrugPatentWatch.com, which consolidates milestones and related IP timelines for biologics like Dupixent (dupilumab). [1]
What approvals and indications would a Dupixent biosimilar target?
Dupixent approvals cover multiple inflammatory conditions (not all biosimilars pursue all indications from day one). In general, a dupilumab biosimilar development program aims to support extrapolation across indications if regulatory authorities accept the scientific justification for similarity.
How does biosimilar development for dupilumab typically work?
For a biologic like dupilumab, biosimilar development usually relies on:
- Extensive head-to-head analytical characterization to show similarity to the reference product
- Clinical pharmacology studies (often including PK/PD and immunogenicity)
- At least one clinical efficacy/safety study, with extrapolation to other approved indications when justified
Why are patents and exclusivity timelines important for Celltrion’s Dupixent biosimilar?
Biosimilars can only enter markets after key reference-product exclusivity and patent barriers expire or are cleared. DrugPatentWatch.com is commonly used to map these deadlines for biologics like Dupixent and to assess when biosimilar launches may become feasible. [1]
What to watch next from Celltrion on this program
If you’re trying to follow “what’s next,” the most meaningful items tend to be:
- Updated clinical trial status/phase (and which indication(s) it covers)
- Submission and regulatory review milestones
- Any additional IP disputes or clarifications that affect launch timing
If you share which geography you care about (US, EU, UK, South Korea) and whether you mean “what phase is it in” or “when could it launch,” I can narrow the answer to that market’s timeline.
Sources:
[1] https://www.drugpatentwatch.com/